Abstract
Although evidence-based treatments for Prolonged Grief Disorder (PGD) exist, pretreatment characteristics associated with differential improvement trajectories have not been identified. To identify clinical factors relevant to optimizing PGD treatment outcomes, we used unsupervised and supervised machine learning to study treatment effects from a double-blinded, placebo-controlled, randomized clinical trial. Participants were randomized into four treatment groups for 20 weeks: citalopram with grief-informed clinical management, citalopram with prolonged grief disorder therapy (PGDT), pill placebo with PGDT, or pill placebo with clinical management. The trial included 333 PGD patients aged 18–95 years (Mage = 53.9; SD ± 14.4), predominantly female (77.4%) and white (84.4%). Symptom trajectories were assessed using latent growth mixture modeling based on Inventory for Complicated Grief scores collected at six time points every 4 weeks. The relationship between patient-level characteristics and assigned trajectories was examined using logistic regression with elastic net regularization based on the administration of citalopram, PGDT, and risk factors for developing PGD. Three distinct response trajectories were identified: lesser severity responders (60%, n = 200), greater severity responders (18.02%, n = 60), and non-responders (21.92%, n = 73). Differences between greater severity responders and non-responders emerged as statistically significant by Week 8. The elastic net model demonstrated acceptable discrimination between responders and non-responders (AUC = .702; accuracy = .684). Higher baseline depression severity, grief-related functional impairment, and absence of PGDT were associated with reduced treatment response likelihood. These findings underscore the importance of early identification of clinical factors to optimize individualized PGD treatment strategies.
Trial Registration: clinicaltrials.gov Identifier: NCT01179568.
Competing Interest Statement
Dr. Shear reported grant funding from the US Department of Defense, Congressionally Directed Medical Research Programs and a contract from Guilford Press to write a book on grief. In the past 3 years Dr. Simon reports receiving grants from the National Institutes of Health (NIH), American Foundation for Suicide Prevention, Patient-Centered Outcomes Research Institute, Ananda Scientific and support from Cohen Veterans Network and MindMed; receiving personal fees from Genomind, Cerevel, Engrail, Praxis; receiving fees or royalties from Wiley (Deputy Editor Depression and Anxiety), Wolters Kluwer (UpToDate) and APA Publishing (Textbook of Anxiety, Trauma and OCD Related Disorders 2020); and having spousal stock from G1 Therapeutics and Zentalis outside the submitted work.
Clinical Trial
NCT01179568
Clinical Protocols
Funding Statement
The study was supported by grants R01MH60783, R01MH085297, R01MH085288, R01MH085308, and P30 MH90333 from the National Institutes of Health and by grant LSRG-S-172-12 from the American Foundation for Suicide Prevention. MM research was supported by K23MH134068 from the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NEW YORK STATE PSYCHIATRIC INSTITUTE - COLUMBIA UNIVERSITY DEPARTMENT OF PSYCHIATRY INSTITUTIONAL REVIEW BOARD
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
